Thomas H. Kean
Thomas H. Kean (R-NJ) bought $1K-$15K of $AMZN (Amazon.com, Inc. - Common Stock) on May 8, 2025, part of 5 transactions in this filing (4 buys, 1 sells).
HillSignal flagged 5 timing concerns on this filing — trades that line up closely with related legislative or contract activity.
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
Suspicious Timing Detected
5 flagsRep. Kean bought $1,001 - $15,000 in $AMZN on 2025-05-08, 14 days before the Access Technology Affordability Act of 2025 (S1918) was introduced, which could benefit Amazon.
Rep. Kean bought $1,001 - $15,000 in $BDX on 2025-05-13, 21 days before the SEPSIS Act (S1929) was introduced, which could create new revenue streams for medical diagnostics.
Rep. Kean bought $1,001 - $15,000 in $TMO on 2025-05-05, 29 days before the SEPSIS Act (S1929) was introduced, which could create new revenue streams for medical diagnostics.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $AMZN | Amazon.com, Inc. - Common Stock | $1K-$15K | $192.08 | — | — | May 8, 2025 |
| BUY | $AON | Aon plc Class A Ordinary Shares | $1K-$15K | $365.06 | — | — | May 27, 2025 |
| BUY | $BDX | Becton, Dickinson and Company Common Stock | $1K-$15K | $137.85 | — | — | May 13, 2025 |
| BUY | $TMO | Thermo Fisher Scientific Inc Common Stock | $1K-$15K | $422.27 | — | — | May 5, 2025 |
| PARTIAL SELL | $CCK | Crown Holdings, Inc. | $1K-$15K | $97.33 | — | — | May 8, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Extreme Heat Economic Study Act of 2025
HR3702 is a procedural early-stage bill that authorizes zero spending. It mandates an economic impact study on extreme heat, not direct contracts or procurement. Real market data shows mixed recent performance across affected tickers: $MCO up 6.49% and $SPGI up 3.74% over 30 days, while $AON is flat at -0.48%. No immediate catalyst for investors.
DeOndra Dixon INCLUDE Project Act of 2025
HR3491 (DeOndra Dixon INCLUDE Project Act) authorizes a Down syndrome research program at NIH but appropriates zero funding. With only 5 procedural actions over a year and stalled committee markup, the bill has no near-term market impact. No public companies are directly affected.
CREATE JOBS Act
The CREATE JOBS Act (S.2056) proposes permanently reinstating 100% bonus depreciation for all U.S. businesses, a proven tax incentive reducing the after-tax cost of capital equipment by 21% in year one. At current market prices, capital-intensive companies like CAT ($810.05), DE ($560.02), FDX ($388.59), and AMZN ($263.04) have already shown strong 30-day momentum (CAT +21.37%, FDX +13.7%, AMZN +30.9%), reflecting broader economic expectations this tax policy reinforces. The bill is in early committee stage with legislative risk high, but identical House companion HR3967 improves odds of eventual enactment.
Lowering Broadband Costs for Consumers Act of 2025
HR4032 (Lowering Broadband Costs for Consumers Act) is an early-stage bill that would expand USF contribution requirements to broadband and edge providers. It remains in committee with no floor action, making near-term market impact negligible. If passed, $CMCSA, $T, $VZ, $GOOGL, $META, $AMZN, and $NFLX would face new recurring costs reducing segment margins by an estimated 1-3%.
Price Gouging Prevention Act of 2025
The Price Gouging Prevention Act of 2025 (HR4528) is an early-stage House bill capping corporate margins during 'exceptional market shocks'. Currently referred to committee with zero appropriations, the bill poses a structural long-term regulatory risk to all large-cap companies with pricing flexibility, particularly retailers ($WMT, $AMZN) and integrated energy ($XOM, $CVX). Near-term market impact is low given early legislative stage, but the bill's breadth — covering all goods and services — represents a significant expansion of FTC authority if it advances.
Access Technology Affordability Act of 2025
S. 1918 is an early-stage, low-probability bill proposing a refundable tax credit for blind individuals purchasing access technology. It creates no direct revenue stream for any public company and has negligible near-term market impact.
STOP CSAM Act of 2025
The STOP CSAM Act (S.1829) has advanced to the Senate calendar, increasing passage probability. The bill mandates elevated content moderation and reporting requirements for major tech and telecom companies, directly increasing compliance costs. Affected tickers include $META, $GOOGL, $MSFT, $AMZN, $VZ, $T, and $TWLO. Market data shows strong recent rallies in tech stocks ($GOOGL +27.95%, $META +24.75%, $AMZN +30.9% over 30 days), creating potential downside risk if compliance cost headwinds materialize.
Streamlining Federal Cybersecurity Regulations Act of 2025
S.1875 is an early-stage procedural bill to create an interagency committee for harmonizing federal cybersecurity regulations. It contains no funding, no mandates, and no procurement directives. Near-term market impact is negligible.
IGNITEACTION LLC: $16.1M Department of Commerce Contract
This $16.1 million contract to IGNITEACTION LLC for cloud infrastructure support at the U.S. Census Bureau represents a steady demand for IT modernization services, likely benefiting major cloud providers and IT consulting firms. While IGNITEACTION is private, this award signals continued federal investment in cloud migration, a positive trend for the broader technology sector.
SEPSIS Act
The SEPSIS Act (S.1929) is an early-stage authorization bill that would create federal programs for sepsis research, education, and data collection. It authorizes but does not appropriate funding, and with only 6 cosponsors and referral to committee in June 2025, passage remains uncertain. Real market data shows all four diagnostic/lab stocks have declined 1-6% in the past week and 2-10% over 30 days, reflecting broader market pressure on healthcare despite the legislative catalyst.
Other Filings by Thomas H. Kean
Free — no credit card
Get the next Kean trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.